Mga Batayang Estadistika
| LEI | 549300T31SMMJ2DDLI13 |
| CIK | 1509745 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Leap Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2025 |
Exhibit 10.1 FIFTH AMENDMENT TO LEASE This is a Fifth Amendment to Lease dated as of July 1, 2025 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (“Landlord”) and Leap Therapeutics, Inc., a Delaware corporation (“Tenant”). WHEREAS, Landlord and Tenant entered into a Lease dated November 13, 2018, as amended by First Amendment to Lease dated August 17, 2021, |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| August 14, 2025 |
Leap Therapeutics Reports Second Quarter 2025 Financial Results Exhibit 99.1 Leap Therapeutics Reports Second Quarter 2025 Financial Results Cambridge, MA – August 14, 2025 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: · Board of Directors initiated process of exploring strategic alternatives to m |
|
| June 23, 2025 |
Exhibit 99.1 Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to ma |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2025 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| June 23, 2025 |
Exhibit 99.2 company presentation LEAP THERAPEUTICS June 23, 2025 Forward looking statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborations and partnershi |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| May 13, 2025 |
Leap Therapeutics Reports First Quarter 2025 Financial Results Exhibit 99.1 Leap Therapeutics Reports First Quarter 2025 Financial Results Cambridge, MA – May 13, 2025 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: · Reported positive data from the randomized, controlled Part B of the Phase 2 DeFia |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2025 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2025 |
Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET Cambridge, MA – March 26, 2025 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
Subsidiaries of Leap Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF LEAP THERAPEUTICS, INC. Subsidiary Jurisdiction of Incorporation/Organization GITR, Inc. Delaware Leap Securities Corp. Massachusetts HealthCare Pharmaceuticals Pty Ltd. Australia Flame Biosciences LLC Delaware |
|
| March 26, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Leap Therapeutics, Inc. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-379 |
|
| March 26, 2025 |
Exhibit 99.2 Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior a |
|
| March 26, 2025 |
Exhibit 99.3 company presentation LEAP THERAPEUTICS March 26, 2025 Forward looking statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborations and partnersh |
|
| March 26, 2025 |
Exhibit 19.1 LEAP THERAPEUTICS, INC. Insider Trading Policy I. INTRODUCTION This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Leap Therapeutics, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors has adopted this Po |
|
| March 17, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2025 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| January 28, 2025 |
Exhibit 99.2 company presentation LEAP THERAPEUTICS Sirexatamab (DKN - 01) Clinical Development Initial Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study January 28, 2025 Forward looking statements 2 This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained |
|
| January 28, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 28, 2025 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| January 28, 2025 |
Exhibit 99.1 Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR bene |
|
| November 14, 2024 |
LPTX / Leap Therapeutics, Inc. / BALYASNY ASSET MANAGEMENT LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Leap Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| November 14, 2024 |
EX-99.1 2 d878621dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value per share, of Leap Therapeu |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| November 13, 2024 |
Leap Therapeutics Reports Third Quarter 2024 Financial Results Exhibit 99.1 Leap Therapeutics Reports Third Quarter 2024 Financial Results Cambridge, MA – November 13, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: · Completed enrollment in the expanded randomized controlled P |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Leap Therapeutics, Inc. |
|
| October 31, 2024 |
LPTX / Leap Therapeutics, Inc. / Beigene, Ltd. - SC 13D/A Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Information to be Included in Statements Filed Pursuant to 240.13d-1(a) and Amendments Thereto Filed Pursuant to 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities |
|
| September 30, 2024 |
Exhibit 99.1 Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Cambridge, MA – September 30, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the rando |
|
| September 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| August 12, 2024 |
Exhibit 10.2 Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. FIRST AMENDED AND RESTATED COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (the “Agreement”) is made effective as of April 2 |
|
| August 12, 2024 |
Leap Therapeutics Reports Second Quarter 2024 Financial Results Exhibit 99.1 Leap Therapeutics Reports Second Quarter 2024 Financial Results Cambridge, MA – August 12, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: · Overall response rate (ORR) increases to 33% across all evaluable |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 23, 2024 |
Leap Therapeutics, Inc. 14,184,397 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-279340 Prospectus Leap Therapeutics, Inc. 14,184,397 Shares Common Stock This prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of up to an aggregate of 14,184,397 shares of our common stock, par value $0.001 per share, which consist of (i) 1 |
|
| May 21, 2024 |
Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 May 21, 2024 Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 May 21, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jimmy McNamara Re: Leap Therapeutics, Inc. — Registration Statement on Form S-3 (File No. 333-279340) (the “Registration Statement”) Dear Mr. McNamara: Pursuant |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| May 13, 2024 |
Leap Therapeutics Reports First Quarter 2024 Financial Results Exhibit 99.1 Leap Therapeutics Reports First Quarter 2024 Financial Results Cambridge, MA – May 13, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: · Completed $40 million private placement financing with participation |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2024 |
Exhibit 10.1 FOURTH AMENDMENT TO LEASE This is a Fourth Amendment to Lease dated as of January 3, 2024 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (“Landlord”) and Leap Therapeutics, Inc., a Delaware corporation (“Tenant”). WHEREAS, Landlord and Tenant entered into a Lease dated November 13, 2018, as amended by First Amendment to Lease dated August 17, 2 |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Leap Therapeutics, Inc. |
|
| May 7, 2024 |
Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 May 7, 2024 Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 May 7, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Leap Therapeutics, Inc. — Registration Statement on Form S-3 (File No. 333-278015) (the “Registration Statement”) Dear Ms. Gama: Pursuant to Rule 46 |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| April 25, 2024 |
LPTX / Leap Therapeutics, Inc. / Samsara BioCapital, L.P. - SC 13G Passive Investment SC 13G 1 tm2412671d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Leap Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 52187K101 (CUSIP Number) April 15, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| April 19, 2024 |
LPTX / Leap Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) April 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| April 11, 2024 |
Exhibit 4.1 LEAP THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: April [●], 2024 Leap Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its permitted regis |
|
| April 11, 2024 |
Form of Securities Purchase Agreement by and among the Company and the purchasers named therein Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, among Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser whose name is set forth on Exhibit A (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company and the undersigned Purchasers are executing and delivering this Agr |
|
| April 11, 2024 |
company presentation LEAP THERAPEUTICS April 2024 Exhibit 99.2 company presentation LEAP THERAPEUTICS April 2024 Forward looking statements 2 This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborations and partnership |
|
| April 11, 2024 |
Exhibit 99.1 Leap Therapeutics Announces $40 Million Private Placement Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program Cambridge, MA – April 11, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| March 18, 2024 |
As filed with the Securities and Exchange Commission on March 18, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 18, 2024. |
|
| March 18, 2024 |
Subsidiaries of Leap Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF LEAP THERAPEUTICS, INC. Subsidiary Jurisdiction of Incorporation/Organization GITR, Inc. Delaware Leap Securities Corp. Massachusetts HealthCare Pharmaceuticals Pty Ltd. Australia Flame Biosciences LLC Delaware |
|
| March 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-379 |
|
| March 18, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Leap Therapeutics, Inc. |
|
| March 18, 2024 |
Amendment No. 1 to Leap Therapeutics, Inc. 2022 Equity Incentive Plan Exhibit 10.33 LEAP THERAPEUTICS, INC. AMENDMENT NO. 1 TO THE 2022 EQUITY INCENTIVE PLAN This AMENDMENT No. 1 (this “Amendment”) to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan (the “Plan”) was adopted on Apri 13, 2023 by the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) by unanimous written consent in lieu of a special meeting, subject to the approval of the |
|
| March 18, 2024 |
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Cambridge, MA – March 18, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: · Presented new clinical data from Part A |
|
| March 18, 2024 |
Leap Therapeutics, Inc. Compensation Clawback Policy Exhibit 97.1 LEAP THERAPEUTICS, INC. COMPENSATION RECOUPMENT POLICY The Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) in order to implement a mandatory clawback policy in the event of a Restatement in compliance with the Applicable Rules (each, as defined below) to be administered by the Board’s Compensat |
|
| February 14, 2024 |
EX-99.1 2 d753642dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
LPTX / Leap Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K 200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 26, 2024 |
As filed with the Securities and Exchange Commission on January 26, 2024 As filed with the Securities and Exchange Commission on January 26, 2024 Registration No. |
|
| January 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Leap Therapeutics, Inc. |
|
| January 23, 2024 |
Exhibit 99.1 company presentation LEAP THERAPEUTICS January 23, 2024 Forward looking statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborations and partner |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| January 16, 2024 |
Exhibit 99.1 Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2024 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEAP THERAPEUTICS, INC. LEAP THERAPEUTICS, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Leap Therapeutics, Inc. SECOND: Article FOURTH of the Fourth Ame |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| November 13, 2023 |
Leap Therapeutics Reports Third Quarter 2023 Financial Results Exhibit 99.1 Leap Therapeutics Reports Third Quarter 2023 Financial Results Cambridge, MA – November 13, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023. “Leap continued to make great strides this quarter including advancing into the |
|
| November 13, 2023 |
Exhibit 3.2 CERTIFICATE OF ELIMINATION OF THE SERIES X NON-VOTING CONVERTIBLE PREFERRED STOCK OF LEAP THERAPEUTICS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Leap Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corp |
|
| September 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| September 13, 2023 |
Exhibit 99.1 company presentation LEAP THERAPEUTICS September 13, 2023 Forward looking statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborations and partn |
|
| August 30, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Leap Therapeutics, Inc. |
|
| August 30, 2023 |
As filed with the Securities and Exchange Commission on August 30, 2023 As filed with the Securities and Exchange Commission on August 30, 2023 Registration No. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2023 |
Leap Therapeutics Reports Second Quarter 2023 Financial Results Exhibit 99.1 Leap Therapeutics Reports Second Quarter 2023 Financial Results Cambridge, MA – August 14, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023. Leap Highlights: · Announced that initial data from Part A of the Phase 2 DeFianCe study |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| July 12, 2023 |
Exhibit 99.1 Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients Cambridge, MA – July 12, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 pa |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| June 20, 2023 |
Leap Therapeutics Announces Reverse Stock Split Exhibit 99.1 Leap Therapeutics Announces Reverse Stock Split Cambridge, MA – June 20, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023. Leap expects its common stock |
|
| June 14, 2023 |
Leap Therapeutics, Inc. 162,677,093 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Regstration No. 333-271399 Prospectus Leap Therapeutics, Inc. 162,677,093 Shares Common Stock This prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of up to an aggregate of 162,677,093 shares of our common stock, par value $0.001 per share, which consist of (i) |
|
| June 12, 2023 |
Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 June 12, 2023 Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 June 12, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Lauren Hamill Re: Leap Therapeutics, Inc. — Registration Statement on Form S-3 (File No. 333-271399) (the “Registration Statement”) Dear Ms. Hamill: Pursuant to Rule 46 |
|
| June 9, 2023 |
Calculation of Filing Fee Table EX-FILING FEES 4 tm2313391d4ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Leap Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Proposed Maximu |
|
| June 9, 2023 |
As filed with the Securities and Exchange Commission on June 9, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 9, 2023 Registration No. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 25, 2023 |
Exhibit 99.1 Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting · 19.5 months median OS in the overall first-line patient population, exceeding current benchmarks · Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overal |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2023 |
Form of Warrant, dated May 6, 2020, by and among the Flame Biosciences, Inc. and the Warrantholders. Exhibit 4.1 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH TRANSACTION UNDER APPLICABLE SECUR |
|
| May 15, 2023 |
Exhibit 10.7 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Second Amendment (the “Amendment”) to Executive Employment Agreement is made and entered into as of this 3rd day of April, 2023 (the “Amendment Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason S. Baum (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company currently employs |
|
| May 15, 2023 |
Exhibit 10.2 Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (the “Agreement”) is made effective as of August 10, 2020 (the “Effective Da |
|
| May 15, 2023 |
Leap Therapeutics Reports First Quarter 2023 Financial Results Exhibit 99.1 Leap Therapeutics Reports First Quarter 2023 Financial Results Cambridge, MA – May 15, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for first quarter ended March 31, 2023. Leap Highlights: · Presenting new long-term follow-up data from Part A of the Phase 2 DisTin |
|
| May 15, 2023 |
Exhibit 10.1 Execution Copy CONFIDENTIAL Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT This STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT (this “A |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| May 15, 2023 |
Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is made and entered into as of this 10th day of August, 2020 (the “Effective Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason S. Baum (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company desires to employ the Executive as the Vice President, Hea |
|
| May 15, 2023 |
Exhibit 10.5 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Second Amendment (the “Amendment”) to Executive Employment Agreement is made and entered into as of this 3rd day of April, 2023 (the “Amendment Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and John Mark O’Mahony (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company currently e |
|
| April 28, 2023 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2023 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| April 26, 2023 |
Exhibit 99.1 Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting Cambridge, MA – April 26, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be pr |
|
| April 21, 2023 |
As filed with the Securities and Exchange Commission on April 21, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 21, 2023 Registration No. |
|
| April 21, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Leap Therapeutics, Inc. |
|
| April 14, 2023 |
Preliminary Proxy Statement on Schedule 14A, filed with the SEC on April 14, 2023 PRE 14A 1 tm231913-1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 12, 2023 |
Exhibit 99.1 Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Cambridge, MA – April 12, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in Part A of the Phase 2 DeFianC |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| April 7, 2023 |
Exhibit 10.1 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Second Amendment (the “Amendment”) to Executive Employment Agreement is made and entered into as of this 3rd day of April, 2023 (the “Amendment Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Cynthia Sirard (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company currently emplo |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incor |
|
| March 24, 2023 |
Subsidiaries of Leap Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES OF LEAP THERAPEUTICS, INC. Subsidiary Jurisdiction of Incorporation/Organization GITR, Inc. Delaware Leap Securities Corp. Massachusetts HealthCare Pharmaceuticals Pty Ltd. Australia Flame Biosciences LLC Delaware |
|
| March 24, 2023 |
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Cambridge, MA – March 24, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022. Leap Highlights: · Acquired Flame Biosciences, adding FL-3 |
|
| March 24, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incor |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-379 |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| March 16, 2023 |
Exhibit 10.1 March 16, 2023 BeiGene, Ltd. c/o Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue Camana Bay PO Box 1348 Grand Cayman, KY1-1108 Cayman Islands Attention: Chairman and Chief Executive Officer RE: Termination of Option and License; Continued Clinical Collaboration Ladies and Gentlemen, Reference is hereby made to (i) that certain Exclusive Option and License Agreeme |
|
| March 16, 2023 |
Exhibit 99.1 Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration Cambridge, MA – March 16, 2023 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that BeiGene’s option under the Ex |
|
| March 16, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF SPECIAL VOTING STOCK OF LEAP THERAPEUTICS, INC. Leap Therapeutics, Inc., a corporation organized under and existing under the laws of the State of Delaware (the “Corporation”), certifies that: FIRST: The name of the Corporation is Leap Therapeutics, Inc. The Corporation was originally incorporated pursuant to the General Corpora |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2023 |
LPTX / Leap Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K 101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 6, 2023 |
As filed with the Securities and Exchange Commission on February 6, 2023 As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. |
|
| February 6, 2023 |
EX-FILING FEES 4 tm235513d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Leap Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Proposed Maximum |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| January 23, 2023 |
Exhibit 3.1 LEAP THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Leap Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted b |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| January 23, 2023 |
Exhibit 10.2 Execution Version SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of January 17, 2023, is made by and among Leap Therapeutics, Inc., a Delaware corporation (“Leap”), and HCV VIII Liquidating Trust (“Stockholder”). WHEREAS, pursuant to the Agreement and Plan of Merger, entered into on or around the date hereof, by and among Leap, Fire Merger Sub, Inc., a Delaware |
|
| January 23, 2023 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of January 17, 2023, by and among Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and those persons that (i) as of the date of this Agreement become or have become entitled to receive Registrable Securities (as defined in Section 1 below) pursuant to, and in accordance with, |
|
| January 23, 2023 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: LEAP THERAPEUTICS, INC., a Delaware corporation; FIRE MERGER SUB, INC., a Delaware corporation; FLAME BIOSCIENCES LLC, a Delaware limited liability company; FLAME BIOSCIENCES, INC., a Delaware corporation, and Shareholder Representative Services LLC, as the Stockholder Representative Dated as of January 17, 2023 |
|
| January 23, 2023 |
Exhibit 10.1 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of January 17, 2023, is made by and among Leap Therapeutics, Inc., a Delaware corporation (“Leap”), and HealthCare Ventures IX, L.P., a Delaware limited partnership (“Stockholder”). WHEREAS, pursuant to the Agreement and Plan of Merger, entered into on or around the date hereof, by and among Leap, Fire Merger Sub, I |
|
| January 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| January 17, 2023 |
Joint Press Release dated January 17, 2023. Exhibit 99.1 Leap Therapeutics Acquires Flame Biosciences Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap’s pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today Cambridge, MA – January 17, 2023 – Leap Therapeutic |
|
| January 17, 2023 |
Exhibit 99.1 Leap Therapeutics Acquires Flame Biosciences Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap’s pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today Cambridge, MA – January 17, 2023 – Leap Therapeutic |
|
| January 17, 2023 |
DEFA14A 1 tm233557d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2023 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other j |
|
| November 14, 2022 |
Leap Therapeutics Reports Third Quarter 2022 Financial Results Exhibit 99.1 Leap Therapeutics Reports Third Quarter 2022 Financial Results CAMBRIDGE, Mass., November 14, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022. Leap Highlights: ? Presented clinical data from Part A of the DisTinGuish stu |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2022 |
Exhibit 99.1 Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting 55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial Cambridge, |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| September 7, 2022 |
Exhibit 99.2 Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq? at the ESMO Congress Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survi |
|
| September 7, 2022 |
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors Exhibit 99.1 Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors Cambridge, MA ? September 6, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 20 |
|
| September 7, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 1, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 17, 2022 As filed with the Securities and Exchange Commission on August 17, 2022 Registration No. |
|
| August 17, 2022 |
Exhibit 99.1 Appendix A 2022 Leap Therapeutics, Inc. Equity Incentive Plan LEAP THERAPEUTICS, INC. 2022 EQUITY INCENTIVE PLAN TABLE OF CONTENTS 1. Purpose A-1 2. Definitions A-1 3. Term of the Plan A-4 4. Stock Subject to the Plan A-4 5. Administration A-5 6. Authorization of Grants A-5 7. Specific Terms of Awards A-6 8. Adjustment Provisions A-10 9. Change of Control A-13 10. Settlement of Awards |
|
| August 17, 2022 |
EX-FILING FEES 5 tm2223589d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Leap Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security type Security class title Fee calculation or carry forward rule Amount registered(1) Proposed maximum offering price pe |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE This is a Third Amendment to Lease dated as of May 16, 2022 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (?Landlord?) and Leap Therapeutics, Inc., a Delaware corporation (?Tenant?). WHEREAS, Landlord and Tenant entered into a Lease dated November 13, 2018, as amended by First Amendment to Lease dated August 17, 2021 a |
|
| August 12, 2022 |
Exhibit 99.2 Leap Therapeutics? Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute Dr. Bertagnolli to Transition Off Leap?s Board of Directors CAMBRIDGE, Mass., August 12, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member |
|
| August 12, 2022 |
Leap Therapeutics Reports Second Quarter 2022 Financial Results Exhibit 99.1 Leap Therapeutics Reports Second Quarter 2022 Financial Results CAMBRIDGE, Mass., August 12, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2022. Leap Highlights: ? Initiation of Part C of the ongoing DisTinGuish study to evalua |
|
| July 12, 2022 |
Exhibit 99.2 Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with BeiGene Leap to host R&D Day today at 12:00 p.m. ET CAMBRIDGE, Mass., July 12, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnol |
|
| July 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| July 12, 2022 |
company presentation LEAP THERAPEUTICS DKN - 01 R&D Day July 12, 2022 Exhibit 99.1 company presentation LEAP THERAPEUTICS DKN - 01 R&D Day July 12, 2022 Forward looking statements 2 This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborat |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 16, 2022 Date of report (Date of earliest event reported) Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2022 |
Leap Therapeutics Reports First Quarter 2022 Financial Results Exhibit 99.1 Leap Therapeutics Reports First Quarter 2022 Financial Results CAMBRIDGE, Mass., May 13, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2022. Leap Highlights: ? Presented positive new data from the DisTinGuish Study of DKN-01 pl |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 11, 2022 |
Exhibit 10.27 ? SECOND AMENDMENT TO LEASE This is a Second Amendment to Lease dated as of October 1, 2021 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership ("Landlord") and Leap Therapeutics, Inc., a Delaware corporation ("Tenant"). WHEREAS, Landlord and Tenant entered into a Lease dated November 13, 2018, as amended by First Amendment to Lease dated August 17 |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2022 |
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Cambridge, MA ? March 11, 2022 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021. Leap Highlights: ? Presented positive new data from the Di |
|
| March 11, 2022 |
Subsidiaries of Leap Therapeutics, Inc. Exhibit 21.1 ? ? SUBSIDIARIES OF LEAP THERAPEUTICS, INC. ? ? ? ? Subsidiary Jurisdiction of Incorporation/Organization ? ? ? GITR, Inc. ? Delaware ? ? ? Leap Securities Corp. ? Massachusetts ? ? ? HealthCare Pharmaceuticals Pty Ltd. ? Australia ? |
|
| March 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| February 15, 2022 |
LPTX / Leap Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K 101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 15, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 11, 2022 |
LPTX / Leap Therapeutics Inc / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d191288dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) LEAP THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 10, 2022 |
LPTX / Leap Therapeutics Inc / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 2)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 52187K101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2022 |
Exhibit 99.1 Power of Attorney The undersigned, ELI LILLY AND COMPANY, a corporation duly organized under the laws of the State of Indiana, United States (the ?Company?), does hereby make, constitute and appoint each of Anat Hakim, Christopher Anderson and Jonathan Groff acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on |
|
| January 28, 2022 |
As filed with the Securities and Exchange Commission on January 28, 2022 S-8 1 tm224676d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on January 28, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4412575 (State or other jurisdiction of incor |
|
| January 18, 2022 |
Exhibit 99.1 Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium - ????DKN-01 plus tislelizumab demonstrated encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients - ????10.7 months PFS in overall first-line population; higher 11.9 months PFS in DKK |
|
| January 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2022 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| November 12, 2021 |
Leap Therapeutics Reports Third Quarter 2021 Financial Results Exhibit 99.1 Leap Therapeutics Reports Third Quarter 2021 Financial Results Cambridge, MA ? November 12, 2021 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2021. Leap Third Quarter Highlights: ? Completed a $103.6 million public offering of |
|
| November 12, 2021 |
Exhibit 10.1 ? FIRST AMENDMENT TO LEASE ? This is a First Amendment to Lease dated as of August 17, 2021 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (?Landlord?) and Leap Therapeutics, Inc., a Delaware corporation (?Tenant?). WHEREAS, Landlord and Tenant entered into a Lease (?Lease?) dated November 13, 2018 with respect to certain premises at 47 Thorndi |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| September 29, 2021 |
LPTX / Leap Therapeutics Inc / Beigene, Ltd. - SC 13D/A Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to 240.13d-1(a) and Amendments Thereto Filed Pursuant to 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) |
|
| September 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| September 24, 2021 |
Exhibit 99.1 Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters? Option to Purchase Additional Shares Cambridge, MA ? September 24, 2021 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27, |
|
| September 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| September 22, 2021 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-248797? PROSPECTUS SUPPLEMENT (To Prospectus dated October 16, 2020) ? LEAP THERAPEUTICS, INC. ? ? ? 22,828,072 Shares of Common Stock Pre-Funded Warrants to Purchase 8,771,928 Shares of Common Stock ? We are offering 22,828,072 shares of our common stock, par value $0.001 per share and, in lieu of common stock, we are offer |
|
| September 22, 2021 |
Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants Exhibit 99.1 Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants Cambridge, MA ? September 22, 2021 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share an |
|
| September 22, 2021 |
Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 LEAP THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: September [], 2021 Leap Therapeutics, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its permitted regi |
|
| September 22, 2021 |
Exhibit 1.1 22,828,072 Shares of Common Stock Pre-Funded Warrants to Purchase 8,771,928 Shares of Common Stock Leap Therapeutics, Inc. UNDERWRITING AGREEMENT September 22, 2021 PIPER SANDLER & CO. Raymond James & Associates, Inc. As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o R |
|
| September 21, 2021 |
Exhibit 99.2 Company Overview September 2021 Leap Therapeutics | Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, proje |
|
| September 21, 2021 |
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Exhibit 99.1 Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Cambridge, MA ? September 21, 2021 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap inte |
|
| September 21, 2021 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 21, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| September 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| September 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| September 16, 2021 |
Exhibit 99.2 DKN-01 in Combination with Tislelizumab and Chemotherapy as a First-line Therapy in Unselected Patients with Advanced Gastroesophageal Adenocarcinoma (GEA): DisTinGuish Trial Samuel J. Klempnera, Joseph Chaob, Vi K. Chiuc, Devalingam Mahalingamd, Hope Uronise, Cynthia A. Sirardf, Michael Kageyf, Jason Baumf, James Songg, Jin Wangg, Farshid Dayyanih, Syma Iqbali, Mohamedtaki Tejanij, M |
|
| September 16, 2021 |
Exhibit 99.1 Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress - ???DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer - ???Additional data presented today showed responses to treatment are independent of PD-L1 expression, with 7 |
|
| September 13, 2021 |
Exhibit 99.1 Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer - In patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in patients with DKK1-high t |
|
| September 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commiss |
|
| August 13, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First Amendment (the “Amendment”) to Executive Employment Agreement is made and entered into as of this 15th day of April, 2021 (the “Amendment Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Cynthia Sirard (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company currently employ |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 13, 2021 |
Exhibit 10.2 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First Amendment (the “Amendment”) to Executive Employment Agreement is made and entered into as of this 20 day of April, 2021 (the “Amendment Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and John Mark O’Mahony (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company currently empl |
|
| August 13, 2021 |
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation EX-99.1 2 tm2125025d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation Cambridge, MA – August 13, 2021 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provi |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 15, 2021 Date of report (Date of earliest event reported) Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2021 |
Leap Therapeutics Reports First Quarter 2021 Financial Results Exhibit 99.1 Leap Therapeutics Reports First Quarter 2021 Financial Results Cambridge, MA ? May 14, 2021 ? Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2021. Leap First Quarter Highlights: ? Completed enrollment for first-line patient cohort in t |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEU |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 1, 2021 |
EX-99.1 2 tm2111614d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer Cambridge, MA – April 1, 2021 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncol |
|
| April 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission F |
|
| March 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commission |
|
| March 22, 2021 |
EX-99.1 2 tm2110451d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer · DKN-01 Monotherapy Demonstrated Clinical Activity in Patients with Endometrial Cancer · Tumoral DKK1 Expression Biomarker Predicts Strongest Outcomes · Conference Call to Discuss Results Today at 8:30 a.m. Eastern T |
|
| March 16, 2021 |
Registration Statement on Form S-8, File No. 333-254360, filed on March 16, 2021. As filed with the Securities and Exchange Commission on March 16, 2021 Registration No. |
|
| March 12, 2021 |
Subsidiaries of Leap Therapeutics, Inc. ? Exhibit 21.1? SUBSIDIARIES OF LEAP THERAPEUTICS, INC. Subsidiary ? ? Jurisdiction of Incorporation/Organization ? GITR, Inc. ? ? Delaware ? HealthCare Pharmaceuticals Pty Ltd ? ? Australia ? |
|
| March 12, 2021 |
TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2021 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction (Commission (IRS Employer of i |
|
| March 12, 2021 |
Exhibit 10.19 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (?Agreement?) is made and entered into as of this 10th day of April, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the ?Company?), and John Mark O?Mahony (hereinafter, the ?Executive?). WITNESSETH: WHEREAS, the Company currently employs the Executive as the Vice President, Manufacturing, of the |
|
| March 12, 2021 |
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 2 tm219433d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results Cambridge, MA – March 12, 2021 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020. 2020 Leap High |
|
| March 12, 2021 |
Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (?Agreement?) is made and entered into as of this 10th day of April, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the ?Company?), and Cynthia Sirard (hereinafter, the ?Executive?). WITNESSETH: WHEREAS, the Company currently employs the Executive as the Vice President, Clinical Research and Dev |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K 101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) LEAP THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
EX-99.1 2 d887324dex991.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, par value $0.001 per share, of Leap Therapeutics, Inc., dated as of February 12, 2021, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provi |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| February 16, 2021 |
EX-1 2 d131284dex1.htm EX-1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERC |
|
| December 28, 2020 |
EXHIBIT 2 EXHIBIT 2 POWER OF ATTORNEY Know all men by these presents that Pascal Minne (the “Undersigned”) does hereby make, constitute and appoint Anne Goffard or alternatively Pierre Claudel as a true and lawful attorney-in-fact of the Undersigned with full powers of substitution, for and in the name, place and stead of the Undersigned both in: 1) the Undersigned’s individual capacity, and 2) th |
|
| December 28, 2020 |
EX-99.1 2 d101381dex991.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, par value $0.001 per share, of Leap Therapeutics, Inc., dated as of December 23, 2020, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provi |
|
| December 28, 2020 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) LEAP THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) December 18, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2020 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2020 |
Leap Therapeutics Reports Third Quarter 2020 Financial Results EX-99.1 2 tm2035751d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics Reports Third Quarter 2020 Financial Results Cambridge, MA – November 12, 2020 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2020. Leap Third Quarter Highlights: · F |
|
| November 12, 2020 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is made and entered into as of this 16th day of August, 2020 (the “Effective Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Christine Granfield (hereinafter, the “Executive”). WITNESSETH: WHEREAS, the Company desires to employ the Executive as the Vice Presiden |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THER |
|
| November 9, 2020 |
EX-99.1 2 tm2035428d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics Presents Updated Data for DKN-01 in Esophagogastric Cancer Patients at SITC 2020 35th Annual Meeting · High Levels of Tumoral DKK1 Expression Correlated with Improved Clinical Outcomes in Heterogenous Esophagogastric Cancer Patients Treated with DKN-01 as a Monotherapy or in Combination · DKK1-high Anti-PD-1/PD-L1 Refracto |
|
| November 9, 2020 |
EX-99.2 3 tm2035428d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference · Single Agent Activity Observed for DKN-01 in Recurrent Endometrial Cancer · Clinical Responses and Longer Progression-Free Survival in Patients with Wnt Signaling Alterations and High Tumoral DKK1 Expression · Patients with Wnt Activat |
|
| November 9, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisdiction of incorporation) (Commissio |
|
| October 14, 2020 |
Leap Therapeutics, Inc. 47 Thorndike Street Suite B1-1 Cambridge, MA 02141 T: 617-341-7700 F: 617-341-7701 www.leaptx.com October 14, 2020 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason L. Drory Re: Leap Therapeutics, Inc. Registration Statement on Form S-3 Filed September 14, 2020, as amended Fil |
|
| October 14, 2020 |
As filed with the Securities and Exchange Commission on October 14, 2020. Registration No. 333- 248797 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LEAP THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Orga |
|
| October 14, 2020 |
Form of Indenture, between the Company and one or more trustees to be named (filed herewith). EX-4.20 2 tm2030180d5ex4-20.htm EXHIBIT 4.20 Exhibit 4.20 INDENTURE INDENTURE, dated as of , 20 , among Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referre |
|
| September 24, 2020 |
Exhibit 99.1 Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer Cambridge, MA – September 24, 2020 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast T |
|
| September 24, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2031686-18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2020 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisd |
|
| September 21, 2020 |
Cambridge, MA and Beijing, China – September 21, 2020 EX-99.1 2 tm2031371d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer Cambridge, MA and Beijing, China – September 21, 2020 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and i |
|
| September 21, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2031371d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2020 Leap Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37990 27-4412575 (State or other jurisd |
|
| September 14, 2020 |
S-3 1 tm2030180-1s3.htm S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 14, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LEAP THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of |
|
| September 10, 2020 |
Exhibit 3.2 CERTIFICATE OF ELIMINATION OF THE SERIES B PREFERRED STOCK OF LEAP THERAPEUTICS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Leap Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the Stat |
